Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, which covers methods of using LP-284 to treat mantle cell lymphoma (MCL), double-hit lymphoma (DHL), and other blood cancers. The allowed claims encompass LP-284 as a monotherapy and in combination with several classes of anti-cancer agents. This development is significant because it adds method-of-use protection to Lantern's existing composition-of-matter patent estate for LP-284, potentially extending intellectual property protection into 2042. Such extended exclusivity could enhance the commercial prospects of LP-284 and provide a stronger competitive barrier in the crowded oncology space.
LP-284 is currently being evaluated in an ongoing Phase 1a dose-escalation clinical trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and solid tumors. The drug was developed through Lantern's proprietary RADR artificial intelligence and machine-learning platform, which integrates large-scale genomic and biological data to identify patients most likely to benefit from its therapies. The AI-driven approach aims to transform the cost, pace, and precision of oncology drug development. LP-284 has already received three FDA Orphan Drug Designations, including for MCL, high-grade B-cell lymphoma with MYC and BCL2 rearrangements, and soft tissue sarcomas. These designations underscore the unmet medical need in these aggressive cancers and may provide additional regulatory and commercial advantages.
The patent allowance is a critical milestone for Lantern Pharma, as it reinforces the company's intellectual property portfolio and supports its strategy to advance LP-284 through clinical development. For investors, this news matters because it reduces the risk of generic competition and could translate into longer market exclusivity if LP-284 gains approval. The company's pipeline also includes LP-184 (zirdafulven), LP-300, and its central-nervous-system-focused subsidiary, Starlight Therapeutics, along with its AI subsidiary, Open-Medicine AI. Success in LP-284 could validate the RADR platform and accelerate other programs.
To view the full press release, visit https://ibn.fm/5zEya. The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. MissionIR ("MIR") is a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries. For more information, please visit www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
